ShapeShapeauthorShapecrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShapeShape

Forte Healthcare Limited announces launch of Cryptisel 0.5mg/ml oral solution for calves

Cryptisel is used to reduce oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem

01 April 2021, at 9:00am

Cryptisel contains the active ingredient halofuginone - a potent anticoccidial - used for the prevention and reduction of diarrhoea caused by Cryptosporidium parvum in calves.

Cryptisel is used to reduce oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Cryptisel is used in all new-born calves to break the cycle of transmission and multiplication on-farm.

Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said, “Cryptisel will be a very useful medicine in the control of the most commonly identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves.”

Cryptisel is a prescription medication and is available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.

Cryptisel is the latest addition to Forte Healthcare’s high quality range of generics.

For further information on Cryptisel contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.